May 2009

footlickertreeΒιοτεχνολογία

3 Δεκ 2012 (πριν από 4 χρόνια και 11 μήνες)

315 εμφανίσεις

Life Science
N
ews from Israel


May

2009

Table of contents



1
.

Greetings







4
.
Medical Device

news



7
.

Business Opportunities


2.

Events & Agenda







5
.

Other interesting news



8
.

About us


3.
Biotechnology

news






6.

Spotlight


9.
Contact us


Greeting from the Minister of Commercial Affairs


Dear friends

&
colleagues
,


I am delighted to present to you today the new newsletter service from the
Commercial Affairs Office
at

the Embassy of Israel, London
.

This l
aunch
gives
us

the opportunity to
provide you with more
inform
ation
about the Life
Science industry in Israel.



Though Israeli is a small country with limited resources, Israel stands out as one of
the world's most competitive economies.

Over the last d
ecade,
Israel

has
introduced a
wealth
of groundbreaking and valuable creativity and innovations in Life Science.

Israel ranked 1st in the world for Medical Device patents per capita and fourth in the
world in biotechnology patents per capita
. F
actors c
ontributing to the success of this
burgeoning industry include cooperation between academia and business, an entrepreneurial
spirit, and a highly skilled workforce
.


During the past year we have worked with many
UK
life science companies and arranged many
business opportunities for UK & Israeli companies.
The
opportunities
included
a medical device
event
in London,
a delegation

to Israel from Boots Innovation

and more.


In this economic climate
a
s global demand for breakthrough technologies
,
we believe
tha
t many Israeli companies
can
offe
r

new innovation
s
.

Therefore o
n our agenda there is a
long list of projects and events relating to a wide spectrum of sectors.

One of the major events is
Biomed Israel 2009
which is going to be in

Tel
-
Aviv on June 15
-
17, 20
09.
Biomed Israel 2009

is
the leading international conference covering the fast
-
growing field of innovation in the
biomedical, health care and life sciences industries

and it is my pleasure to invite you to be part of
the UK delegation to BIiomed Israel 2
009 (y
ou can find more details in this newsletter
)
.



The aim of this

Newsletter is to provide you with more information about new technology and
Innovation from
the
Israel
i Life Science industry.
We hope you are going to find this

newsletter
useful and
W
e would appreciate any

feedback
,

suggestions and ideas
regarding this service or any
of our activities.





If you would like to receive more information about
one of the articles below, please

do not
hesitate to

contact us
.
We
will continue to provide a profe
ssional first point of contact and
would
be happy to provide
more
information about Israeli companies an
d technologies
.




Gil Erez
,



Minister for Commercial Affairs




Embassy of Israel, London


Back

Events & Agenda

Past events

Future events

Boots Innovation visit to Israel


A delegation of seni
or
managers from the
Boots
Innovation

visited Israel in
June 2008. The delegation met with more

than
70 Israeli companies that are developing
innovative consumer products in the
cosmetics, health and quality
-
of
-
life sectors.

Liz Morgan
, director of the company's New
Product Introduction & Development team,
said that the trip to Israel was prompted by
talk about
Israel's prowess as a promising
reservoir of medical equipment

know
-
how.






Meeting between Israeli & UK companies in

Medica
2008

During the biggest Medical Device
exhibition,
Medica

2008 in
Düsseldorf Germany, the Israeli

BIOMED ISRAEL 2009

June 15
-
17, 2009


ILSI
-
Biomed Isra
el 2009, 8th National
Life Science & Technology Week, is
the leading international conference
covering the fast
-
growing field of
innovation in the biomedical, health
care and life sciences industries, is
expected to attract over 6,000 local
and internation
al CEOs, experts,
academics, scientists, researchers,
venture capitalists, and angel
investors.


Biomed 2009 is an
essential
opportunity

to learn from
international experts the latest
healthcare trends, regulatory and
reimbursement issues, and therapies.
A vast variety of Israeli
BioPharma

and
Medical Device players

will also
receive exposure.


Biomed 2009 highlights:



Plenary sessions and
presentations by industry leaders
and academia worldwide
;




The 3rd International
Stem Cell

Meeting
;




Unique opportuniti
es for
networking

and learning
;




Satellite events focusing on
commercial department ar
ranged
over 90
meetings between Israeli and leading UK
healthcare companies

and distributors in order
to explore partnership opportunities.





Israel Life Science event in
Manchester


The Commercial Department at
the Embassy

of Israel in London,
togeth
er with the
British Israeli Chamber of
Commerce North West
,
UK Trade and
Investment North
West

and
MediLink North
West

held the Israeli Life Science Event at the
Deloitte

Offices in Manchester on 25th
February 2009.


60 representatives from north west healthc
are
companies attended the event, which served to
clinical studies,
aesthetic
medicine, orthopaedic
;




One
-
on
-
one partnering meetings
;




Exhibition of the latest medical
innovations
;




Prime location
at

Tel Aviv, a
commercial capital and tourist
d
elight
.



Exhibition's Web Site


Please
contact us



if you wish to hear more information about
our special rates for UK companies.


increase awareness of the Israeli life Science
Industry amongst North West businesses.


The event succeeded in providing the platform
to assemble a delegation for the Israel
BioMed
Event

(June 15


17 2009); as well as serving
to introduce a small number of Israeli
organisations to North West based life
-
science
companies in order to create increased
opportunities and further cooperation with
Isra
el.




For visual map of the Israeli Life
Science map please

Click here



BIO ATLA
NTA 2009



May

1
8
-
21
, 2009



The BIO International Convention is
the largest global event for the
biotechnology industry and attracts
the biggest names in the biotech
industry.



Fifteen Israeli companies

will be
presenting a
t

the BIO International
Conven
tion during May 18
-
21, 2009.



Bio convention provides insight on
the major trends affecting the
industry. Moreover, we are keen to
invite you to learn more about the
Israeli industry and participate in a
networking session, headed by Eli
Opper Israel’s C
hief Scientist, taking
place on May 19th at Georgia World
Congress Center.







Please
contact us

if you would like
to
receive the catalogue of the Israeli

companies
that will be participating
in

Bio
-
Atlanta 2009.



"It's no exaggeration to say that t
he kind of innovation going on in Israel is
critical to the future of the technology business
…”





Bill Gates, 2006



Back

News from
the
Israel
Bio


Technology

Sector


Johnson & Johnson acquir
es Israel’s Omrix for $438 million


Healthcare company
Johnson & Johnson

is buying Israel’s
Omrix

Biopharma

ceuticals for $438
million in cash. The two companies ha
ve collaborated for the past five years.
Omrix
, established in
1995, developed and markets the unique surgical sealant, Quixil.


In describing the acquisition, Alex Gorsky, Company Group Chairman for
Johnson & Johnson

stated, "Our partnership with
Omrix

has already expanded our capacity to provide innovative,
next generation products that raise the standard of surgical
care." Under the


terms of the
agreement, Omrix, a biopharmaceutical company that develops and markets bio
-
surgical and
immunotherapy products, would operate as a stand
-
alone entity and would be reporting through
ETHICON, a Johnson & Johnson company and le
ading provider of suture, mesh, hemostats, and
other products for surgical procedures.


In 2006, Johnson & Johnson purchased Israel's
Colb
ar LifeScience
, a biomaterial product
company.




Teva and Lonza join forces to tap "Biosimilar" drugs market

Israel’s
Teva Pharmaceuticals
, the world’s largest generic drug producer, formed
a strategic partners
hip with Swiss
-
based
Lonza

to exploit the market for generic
versions of biotechnology drugs, also known as biosimilar, that are in high
demand.


Biosimilars are viewed as a promising new market, given t
he pent
-
up demand for cheaper
versions of expensive biotech drugs and are already being sold in Europe. The joint venture,
which aims to develop, manufacture and market a portfolio of drugs, will commence activities in
the first quarter of 2009.



Israeli

scientists link fetal stem cells to tumor development in
a

boy

A family desperate to save a child from a lethal brain disease sought highly
experimental injections


of fetal stem cells


injections that triggered tumors
in the boy's brain and spinal cord
, Israeli scientists reported.

A teenage boy with ataxia telangiectasia
--

a rare genetic disease marked by
the degeneration of certain parts of the brain
--

developed tumors in his brain
and spinal cord after receiving injections of fetal stem cells, Isra
eli researchers
reported. Using stem cells derived from different fetuses that were combined
with growth
-
triggering compounds might have resulted in the abnormal formation of more than
one cell, the lead scientist said
.

Read more

(17.2.09
,
www.yahoo.com
)
.



Turning bacteria against bacteria to fight disease

Superbugs resistant to
antibiotics have become the number one killer in hospitals today. Now
Israeli research offers hope of a solution
-

by getting the bacteria to kill themselves
. N
ew research
from Israeli scientists could give drug developers the upper hand in outsmarting bac
teria
-

by
using their own protective system against them.


Prof. Eshel Ben
-
Jacob
, a scientist at
Tel Aviv University
, discovered that if he exposed a colony

of
bacteria to the same chemical signals that the bacteria produce to fight off competition, they
would end up killing each other. "Our studies suggest this is a new way to fight off bacteria," says
Ben
-
Jacob, an award
-
winning scientist from TAU's School
of Physics and Astronomy. "This
strategy seems very promising
--

it's highly unlikely that the bacteria will develop resistance to a
compound that they themselves produce."

Read more


(1
2
.2.09


www.israel21c.org
)



Perrigo r
eceives F
DA

a
pproval
f
or
n
ew Acne
t
reatment

Perrigo Company

recently received final app
roval from the U.S. Food and Drug Administration
(FDA) to market its new Sulfacetamide Sodium Topical Suspension Lotion, which was determined
to be therapeutically equivalent in its treatment of acne to Sanofi
-
Aventis' commercially
successful Klaron Lotion
.



Perrigo is a leading global healthcare supplier that develops, manufactures and distributes over
the counter (OTC) and generic prescription pharmaceuticals, nutritional products, active
pharmaceutical ingredients (API) and consumer products. It is the
world's largest manufacturer
of OTC pharmaceutical products for the store brand market and is active in the United States,
Israel, Mexico and the United Kingdom.



Searching the ocean floor for a super antibiotic

Israeli researchers are trawling the ocean
to collect marine sponges after discovering that the
creature's defense mechanism could provide a new super
-
antibiotic.

For premature babies, people with AIDS, cancer and transplant patients,
or anyone else with a compromised immune system, fungal infecti
ons are
a serious problem. They may sound like harmless ailments, but they can
beat the best of the world's antibiotics, and for many unlucky people,
contracting a fungal infection can be deadly.


One fungal infection, Cryptococcus neoformans, is thought t
o be
responsible for an estimated one million deaths each year worldwide, including some 600,000 in
sub
-
Saharan Africa. Now Israeli zoologists believe they may have an answer: the common marine
sponge.


Scientists from the Department of Zoology at Tel Avi
v University have identified several
alternative antibiotic candidates among the unique compounds that help a sponge fend off
predators and infections.

Read more


(
15.3
.09


www.israel21c.org
)




EU grants orphan status to Teva
-
Gamida Cell venture's drug

A joint venture of
the Israeli companies
Gamida Cell Ltd.
and Teva Pharmaceutical said the
European Commission granted orphan
-
drug status to StemEx, an investigational treatment for
acute lymphoblastic leukemia and acute myeloid leukemia. The U.S. Food and Drug
Administration granted the drug orphan status in Mar
ch 2005 to provide hematopoietic support in
certain blood
-
cancer patients who are receiving high
-
dose therapy, the venture said in a
statement on Wednesday.

StemEx, being researched as an alternative to a bone
-
marrow transplant, is in an advanced Phase
II
I study in the U.S., Europe and Israel. E.U. rules define orphan drugs as those intended to treat
life
-
threatening or chronic conditions affecting no more than 1 in 2,000 people in the E.U., or
medicines that for economic reasons would not be developed wit
hout incentives. The status
confers 10 years of market exclusivity for the product in the European Union. Teva and Gamida
Cell, which is developing stem
-
cell
-
expansion technologies and therapies, are based in Jerusalem.

(11.09.09
-

www.marketwatch.com
)


Back

News from
the
Israel
Medical
Devices Sector


Israeli
Medical Devices

Start Ups continue to be attractive: Medtronic acquires Ventor

Medtronic Inc
, the world's largest stand
-
alone maker of medical devices, is buying Israeli start
-
up
Ventor Technologies
, Netanya
-
based startup, for $325 m
illion in cash.

Following the acquisition the Israeli company will be known as Medtronic Ventor Israel and will
continue research and development of the product. Ventor, established in 2004, developed a
unique aortic valve prosthesis that will be implante
d in severely ill cardiac patients with heart
valve
-
related diseases to enhance blood supply to the body.


Despite the global credit crisis multinational concerns continue to invest in Israeli expertise. As
global demand for breakthrough technologies in g
eneral and in the field of life sciences in
particular is not affected by the slowdown, and the long R&D processes to allow for such
innovation is ongoing, analysts expect the Israeli sector to be largely safeguarded from financial
pressures.




RESPeRATE

d
evice
n
ow
a
vailable
a
t
l
arger Boots
s
tores

in the UK

InterCure

Ltd., a medical device company publicly traded on the Tel
-
Aviv
Stock Exchange,



announced that RESPeRATE, the world's first FDA
-
cleared
,
over
-
the
-
counter blood pressure treatment device, is now being sold in 100
Boots Pharmacy

stores throughout the UK.


InterCure

is supporting the launch with a variety of advertisements and in
-
store promotions with
Boots
. The new distribution of RESP
eRATE at Boots continues InterCure's
retail momentum. InterCure entered the UK pharmacy market in 2008, achieving broad
distribution at 1,400
Lloyds Pharmacy

stores and continues to expand its footprint in ind
ependent
pharmacies through two wholesalers, Mashco and Colorama.


"Boots is a trusted pharmacy in the UK, with a reputation of being a reliable source of high
-
quality
care," said Erez Gavish, president and CEO of InterCure. "For InterCure, this agreement

marks an
important step in the expansion of RESPeRATE into the retail market, and we are steadfast in our
mission to continue placing RESPeRATE onto pharmacy shelves and into the homes of anyone
seeking a proven, personal therapeutic device."

(17.3.09
-

www.resperate.com
)


"Most admired medical company" St. Jude acquires Mediguide for $283 million

"We believe
MediGuide's

proprietary technology may also extend across a va
riety of other product
categories

We look forward to bringing this technology into our portfolio so that we can further
develop and capture these potential opportunities,” Daniel J. Starks, chairman, president and
chief executive officer of
St. Jude Medical
, said.


St. Jude Medical

is acquiring the Israeli medical
-
technology company
MediGuide
, which develops
technology to guide catheters in m
inimally invasive medical procedures, for $283 million in cash.



MediGuide's

navigation system tracks a tiny sensor mounted on a needle, guide wire, catheter or
other medical device placed in the body by a physi
cian during a catheterization or other minimally
invasive procedure.

MediGuide was founded in 2001 as an internal division of Elbit Systems, which
is one of Israel’s largest defense electronics manufacturers.


Me
diGuide

developed medical uses for guidance technology that the parent company had
developed. Many of the technologies developed by Israel’s defense industry are successfully
adapted to sectors across the board. Mediguide has agreements with Medtronic, Si
emens, Asahi
Intecc of Japan, Boston Scientific, and Philips and will become part of St. Jude's atrial fibrillation
division.



Simbionix and J&J Announce Distribution Agreement at Russia and the CIS Countries

Simbi
onix
, the world's leading developer of medical simulation systems, announced an agreement
with
Johnson & Johnson LLC

for distribution of
Simbionix
's simulators and relat
ed products.


Johnson & Johnson, LLC operates in Russia, Ukraine and CIS countries and is one of the
subsidiaries of Johnson & Johnson.

Johnson & Johnson LLC will have exclusive rights to distribute
Simbionix
's lin
e of advanced medical simulators in hospitals in the Russia and CIS countries.


Simbionix

is a global leader in medical simulation technology. Simbionix mission is to provide
state of the art, computer
-
assisted met
rics
-
based surgical simulation systems, and set the
standard for minimally invasive surgical training and performance.

Simbionix

products provide
medical experts with hands
-
on training in a comprehensive array of M
IS procedures, including; GI
Endoscopy, Endourology, percutaneous access, advanced laparoscopic procedures and
Endovascular procedures.

"In the last year, Simbionix has increased its distribution channels and
its exposure to the international market, "exp
lains Mr. Doron Zilberman,
Simbionix
's VP of
International Sales.
"We see Russia as one of the leading markets in the emerging medical world;
this agreement is an additional step of our on going success in the inte
rnational market ..."


(16.4.09
-

www.prnewswire.co.il
)



Keep baby safe, sound and kicking with Biopad


BioPad
, a
n Israeli company
,

has developed an important new tool th
at enables

mothers
-
to
-
be to see their baby's kicks on a handheld device.

Digital moms, dads, and grandparents
-
to
-
be will be happy to have baby
"connected" to Israel's latest high
-
tech tool. Hooked to an iPhone, Blueberry or
other handheld device from one

end, and a bulging baby belly on the other, the
Biopad device keeps track of baby's kicks and somersaults, inside the womb.

Read m
ore

(17.2.09


www.israel21c.org
)



Lumenis Introduces LightSheer
(R)

Duet(
TM)

for High Speed Permanent Hair Reduction

Lumenis Ltd
., a global developer, manufacturer and seller of laser, light
-
based and radio
-
frequency devices for surgical, aesthetic, and ophthalmic
applications, announced plans to launch the LightSheer(R) Duet(TM) Diode
Laser System for high
-
speed perman
ent hair reduction
.


"The LightSheer Duet is the most exciting innovation in laser hair removal
since LightSheer first revolutionized the industry in 1998. LightSheer Duet
reduces hair removal treatments up to 75% and vastly improves patient
comfort, elimi
nating the need for topical anesthetics. These ground
-
breaking changes will
significantly improve practitioner and patient acceptance of hair removal, as well as increase the
revenue potential for physician practices and clinics," said Mr. Robert Mann, Gen
eral Manager of
Lumenis Global Aesthetics and Dermatology.

Lumenis is Israel’s largest medical device company with more than 800 employees worldwide. The
Company invests heavily in R&D and holds a leading position in the markets in which it serves.
Lumenis

has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over
100 countries, and an installed base of over 70,000 systems.

(
05.03.2009



www.lumenis.com
)



Parkinson's patients dance to a diffe
rent tune

-

see video

An Israeli therapist has developed a unique new dance treatment for patients
suffering Parkinson's disease. The therapy is attracting worldwide attention.


Read m
ore

or
Watch video.



(01.04
.09


www.israel21c.org
)





Back

Other interesting news from Israel

Israeli universities ranked among world's best

The 2008
London
Times Higher Educa
tion

Supplement

has ranked
Israel's
Hebrew University

among the world's top 100 institutions of higher
learning.


The Times report placed the
Hebrew University

93rd in its list of 200 top
Universities. This is a significant improvement for the university from
128th place a year earlier.


The
Technion
-
Israel Institute of Technology

ranked 109th overall and tied for 25th
place among
the top 50 institutions of technology. The
Technion

was also ranked 31st in Natural Sciences
(ahead of Johns Hopkins University, NYU and ranking German institutions).


Tel Aviv University

was listed 114th, an improvement from 151st place last year. The selection
parameters included rankings given by academics of other universities, the number of citations
received, the number of academic reviews and
the ratio of students to lecturers.




Israel at the forefront of patents and innovations

In the 2008
report

of the
World Intellectual Property Organization (WIPO)

on patent activity
throughout the world, Israel placed 15th out of 138 nations in number of patents. In addition, in
the 2008 WEF Competitiveness Report, Israel ranked 5th in utility patents, 3rd in the qu
ality of
scientific papers and 6th in overall innovations.


The WIPO report

also placed Israel as 9th in the availability of scientists and engineers per capita.
The US P
atent Office granted 15,868 patents to Israel between 1977 and 2007, placing the
country 14th in the world after the United States.




Baby boys are troublesome, Israeli gender based study finds

It may sound like an old wives tale, but Israeli medical rese
archers have discovered that the age
-
old stories about boys being more trouble are true
-

at least when they are in the
womb.


Based on data from more than 66,000 women who gave birth at
Is
rael's Rabin
Medical Center

between 1995 and 2006, doctors have come to some interesting
conclusions about baby boys and girls.


The researchers found that male babies are more at risk of being big than females; boys are at
risk of preterm rupture of mem
branes, preterm delivery, abnormal fetal heart rate, and delivery
by vacuum, forceps or cesarean section. Female fetuses on the other hand, are at risk of breech
birth and restricted fetal growth, the study found.

Read more


(
31
.
03
.09


www.israel21c.org
)


Holding out hope of a cure for deafness

Prof. Karen Avraha
m of
Tel Aviv University

has discovered that microRNAs in the 'hair' cells of our
ears are a major cause of deafness, holding out the promise of a potential new cure.


Deafness continues to be a signifi
cant problem in medicine today. For all the progress made in the
last years, still one in 1,000 US babies are born deaf. The numbers increase as the population
grows older, with more than 50 percent of pensioners in America experiencing some form of
hearin
g loss, making it the most common disability in humans. Despite this, doctors still don't
know what causes hearing loss in most people, but they do know where the process starts to
break down.


Avraham, a world
-
renowned geneticist, whose groundbreaking wor
k has previously discovered
four deafness genes and novel mutations in 10 deafness genes, among 46 known ones, looked to
microRNA's for the answer. Avraham discovered that 'hair' cell microRNAs are regulators involved
in the normal development and survival

of cells in the inner ear and are necessary for proper
hearing.


Read more


(
14
.
4
.09


www.israel21c.org
)




Back

Spot Light

on Israeli Company





"This simple outpatient focused ultrasound procedure will be replacingsurgery as we
know it . . . MR
guided focused ultrasound is a tremendous leap forward in the treatment
of uterine fibroids."


Prof. Wladislaw Gedroyc, Consulting Radiologist, St. Mary's Hospital, London, UK


InSightec is a private company that was founded specifically to develop MR (mag
netic resonance)
guided Focused Ultrasound technology. Insightec was founded by merging technology from GE
Healthcare (then GE Medical Systems) and Israel’s Elbit Medical Imaging. The ExAblate 2000, a
combination of Magnetic Resonance imaging and Focused U
ltrasound (MRgFUS) technology, was
created when members of the company's management, Jacob Vortman and Shuki Vitek combined
their know
-
how and experience, after developing night
-
vision systems and the Black Anchor
-

the
target missile used in the trials of

the Arrow missile at Rafael, Israel's Armament Development
Authority. In 2007 the company received FDA approval to use ExAblate 2000 with GE Healthcare’s
3 Tesla MRI System which provides women greater access to the procedure. In the same year the
company

Received the

European CE Mark and USFDA approval for ExAblate 2000 treatment of pain
caused by bone metastases. The ExAblate 2000 makes hysterectomy procedures obsolete and
allows patients to avoid invasive and painful surgery, general anesthesia, extende
d hospitalization,
a lengthy recovery time and multiple side effects.


InSightec has clinical collaborations with leading hospitals and medical research institutions around
the world, including: Women’s Hospital of Harvard, the Mayo Clinic, Johns Hopkins H
ospital,

St.
Mary's Hospital of Imperial College, Germany's Charite Hospital and Japan's IseiKai Hospital.


Insightec has launched an extensive research program to conduct clinical trials using the ExAblate
2000 technology in other applications including

b
reast, bone, brain tumors and liver, while
continuing clinical trials in uterine fibroids.


In 2002 the Business

Week called ExAblate 2000 “one of 25 ideas for a changing world.”
Last

year
the World Economic Forum selected the company as one of its Technol
ogy Pioneers for 2008.


Back

Business opportunities

from Israel

Telcomed Advanced Industries Ltd.

A Medic4All Group Company

This company develops and markets a wireless remote medical monitoring te
chnology.
Medic4All’s systems includes: secure wireless technology for medical data transmission from
the patient’s home or office to a monitoring centre and a web medical file via the telephone
line, Internet or cellular.


Looking for

distributors with m
edical background or IT Integrators dealing with the
healthcare market, homecare services firms, disease management programmes, remote
patient monitoring programmes and tele
-
assistance services.

Visit their website:
w
ww.telcomed.ie

Ref number:
2009/71

For more information about this company, please
contact
us

Common Sense Ltd.

A leading de
veloper of indicators utilizing common hygienic products such as panty liners,
tampons and diapers as a platform for non
-
intrusive diagnosis and health condition
monitoring. Recently, a UK medical publication indicated that the NHS recommended the
use of
one of their products in the hospital setting (AL
-
SENSE


an amniotic fluid leak
detector offered to pregnant women once they reach the hospital).

Looking for

companies in the UK selling products directly to hospitals and the NHS.

Visit their website:
www.cs
-
commonsense.com

Ref number:
2009/72

For more information about this company, please
contact
us

NiliMEDIX Ltd.

Established in 2002, NiliMEDIX Ltd. is a medical device
company committed to developing

safer, easier to use and
more economic tools for Continuous Subcutaneous Insulin
Infusion (CSII) for people with Diabetes. The Nil
iMEDIX
patent
-
protected platform technology is based on a
proprietary pressure triggered release mechanism,
controlled by a unique valve and sensor system.


Looking for

experienced distributors in the UK.

Visit their website:
www.nilimedix.com

Ref number:
2009/73

For more information about this company, please
contact
us

NMB Medical Appl
ications Ltd.

Existent Israel Ltd. is a company dealing in the development and manufacture of innovative
technology in the field of interventional cardiology. They have recently launched their first
product, the Premier Coronary Stent System (CE approved)
. The Premier Coronary Stent is
designed to promote low target vessel revascularization rate (TVR), by pioneering the use of
a superior strength essentially nickel free alloy which enables it to have: the thinnest struts,
the lowest surface coverage area
and significantly less metal than any other coronary stent.

Looking for

distributors in the UK.

Visit their website:
www.existent
-
med.com

Ref number:
2009/74

For more information about this company, please
contact
us

Venus Technologies Ltd.

5 minutes to Visibly Tighter, Smoother Skin

Venus Secret
™ is a personal device for the immediate visible improvement of fine lines and
wrinkles. Designed for individuals with busy, dynamic lifestyles, treatments take
just 5
minutes a day.

Looking for

potential distributors in the UK within the field of the ho
me use
aesthetic market with emphasis based upon TV channels, readers offers and retail
chains.

Visit their website:
www.venustechnologies.com

Ref number:
2009/76

For more information about this company, pl
ease
contact
us


Bio
-
CellProtect

BioCellProtect, develops and markets SR18, a natural substance solution for preventing and
m
inimizing the biological damage of cellular radiation. SR18 is a biochemically proven
human
-
cell fortifer. It enhances the natural defense system of the human cell, which
reduces the risk of the radiation toxicity by 95%. SR18 will be distributed
as an OTC

(Over The
Counter) Medical Device for external use.

Looking for

d
istribution in the UK


Ref number:
2009/77

For more information about this company, please
contact
us


Herbamed Ltd.

This company concentrates on the development of high quality Nutraceuticals and Health
ingredients using proprietary technologies. Their products are supported by cl
inical data.


Looking for

distributors, retailers of health food and food supplements for 3 main products:

1.

Low calorie citrus fiber snack bar


for reducing cholesterol.

2.

Ultrasome


COQ10 tablets or beverages.


3.

Omega fiber health snack bar.

Visit their we
bsite:
www.herbamed.co.il

Ref number:
2009/79

For more information about this company, please
contact
us

Aerodentis

This company has developed a unique Orthodontic device called Aeodentis, for straightening
teeth using constant force for the duration of the treatment. The CE
-
certified device uses a
patented system for moving teeth into

their ideal occlusion using only one device with a pre
-
determined path


a major Orthodontic breakthrough. Designed for use only during evening
and night, Aerodentis is applicable to children as well as to adults.

Looking for

a distributor in the UK.

Vis
it their website:
www.aerodentis.com

Ref number:
2009/78

For more information about this company, please
contact
us

Fischer Pharmaceuticals Ltd.


Fischer Pharmaceuticals Ltd. is a multi
-
national company specializing
in
anti
-
aging skin

and
health care products
. They maintain a strong international presence
in more than 30 markets world
wide, supplying leading retail chains and medical institutions.

Looking for

a local distributor in the UK.

Visit their website:
www.Dr
-
Fischer.com

Ref number: 2009/46

For more information about this company, pleas
e
contact us

IDenta Corp.

IDenta develops, manufactures and distributes innovative on
-
site drug
-
of
-
abuse substance test
ing products to the professional and civilian markets.
Founded by leaders in forensic product design and development, IDenta
offers five rapid and effective drug lab
-
quality identification

field kits with
patented reagents and casings: Marijuana/Hashish,
Cocaine/Crack, Heroin,
Ecstasy (MDMA), MDA, Meth Kits. Easy to use in the home and office as they are in the field
by professionals with 100% accuracy.

Looking for

a UK representative, established and involved, as much as possible, in the
retail
-
consumer
market.


Visit their website:
www.drugsdetector.com

Ref number: 2009/49

For more information about this company, please
contact us

Enzymotec Ltd.

Enzymotec is an Israeli Biotech company, which has become a major
supplier
of high
-
end nutraceuticals

across the world. Recently, few
of their pipeline ingredients came to an advanced develo
pment stage
making them ready to be introduced through Rx channels and the company has decided to
look for business partners who are looking to

in
-
license a branded product, developed and
owned by Enzymotec in the area of CVD, Cognitive solutions for adult
s and children who
suffer from ADHD.

Looking for

a UK agency that will make the contact between Enzymotec and UK pharmacy
companies.

Visit their website:
www.enzymotec.com

Ref number: 2009/50

For more information a
bout this company, please
contact us

Floris Hadas

Floris is a pharmaceutical, VMS (Vitamins Minerals Supplements
-
nutritional) a
nd
cosmetics producer established in 1986. Floris is an Israeli leader in the
development and manufacture of advanced
health care products

thanks to its
innovative R&D and its know
-
how. They also manufacture tailor made
products, private label and subcon
tracting.

Looking for

distributors in the UK for their food supplements. The company
can be small to medium size that has the ability of distribution, sales and marketing the
products to pharmacies, pharm
-
chains, drugstores etc.

Visit their website:
www.floris.co.il

Ref number: 2009/52

For more information about this company, please
contact u
s


Back

About Us


The Commercial Affairs Department at the Embassy of Israel
,
London

is part of the
Ministry of Trade and Labour and the Foreign Trade Administration

in Israel
.


Our

role is to
re
cognise

exciting new opportunities and companies in the Israeli market and facilitate
collaboration and partnership according the needs of the UK.


With a remit covering all areas of the Israeli market, from agriculture to bio
-
technology and from
cosmetics

to telecommunications, the Commercial Office is a proactive key player in the initiation
of new economic and commercial opportunities and the establishment of new business channels
between Israel and the UK.




By providing value added services, it is bec
oming regarded as a beneficial, efficient and reliable
contact point in the UK, where relevant customers can find assistance.


Back

If your colleagues or business contacts would like to read about m
ore
opportunities in Israel, please forward this newsletter to them.


Contac
t

us



This ne
wsletter was produced by
:


T
he Commercial Affairs

Department
,
Embassy of Israel


London

2 PALACE GREEN,

LONDON, W8 4QB


TELEPHONE: +44 (0) 20 7957 9525

FAX:
+44
(
0
)
00

9638

1535


E
-
mail:
london@moital.gov.il

Internet:
http://www.israeltrade.gov.il/uk


To unsubscribe